Status:
RECRUITING
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Lead Sponsor:
Eli Lilly and Company
Conditions:
Obesity
Overweight
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type ...
Eligibility Criteria
Inclusion
- There are no specific eligibility criteria for the Master Protocol.
- See study GZP1 for eligibility criteria relevant to participants with obesity and overweight without type 2 diabetes
- See study GZP2 for eligibility criteria relevant to participants with type 2 diabetes
Exclusion
Key Trial Info
Start Date :
May 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06993792
Start Date
May 15 2025
End Date
August 1 2027
Last Update
December 17 2025
Active Locations (80)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona, United States, 85375
2
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona, United States, 85741
3
Norcal Endocrinology & Internal Medicine
San Ramon, California, United States, 94583
4
Southern California Clinical Research
Santa Ana, California, United States, 92701